<DOC>
	<DOC>NCT02021656</DOC>
	<brief_summary>This study will evaluate the antiviral efficacy of ledipasvir (LDV)/sofosbuvir (SOF) fixed-dose combination (FDC) in treatment-naive and treatment-experienced participants with chronic genotype 1 Hepatitis C Virus (HCV) infection. Participants will receive 12 weeks of treatment and continue assessments during a 24-week follow-up period.</brief_summary>
	<brief_title>Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Sofosbuvir</mesh_term>
	<mesh_term>Ledipasvir</mesh_term>
	<criteria>Key Willing and able to provide written informed consent HCV RNA ≥ 10^4 IU/mL at screening HCV treatmentnaïve (HCV genotype 1), as defined as no prior exposure to any interferon (IFN) or other approved or experimental HCVspecific directacting antiviral agent; OR HCV treatmentexperienced with medical records that include sufficient detail of prior IFNbased treatment to allow for categorization of prior response as either intolerant, nonresponder, or experienced viral breakthrough or relapse. HCV infection documented by antiHCV antibody test, genotyping test, or liver biopsy Key Pregnant or nursing female or male with pregnant female partner Chronic liver disease of a nonHCV etiology Current or prior history of any clinicallysignificant illness (other than HCV) Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV) NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>